Professor Sir Kenneth Calman stated: "The decision in early 1998 to provide central funds to make recombinant products more widely available was driven...by the understandable fear felt by haemophilia patients and their carers in the face of the unknown but theoretical risk of vCJD and against a background of infection with blood borne viruses."